Geriatric Medicine Treat Age-Related Diseases Market Research Report 2016: Hexa Reports
- Submitted by: HexaReports99
- Views: 55
- Category: Other
- Date Submitted: 05/15/2016 11:59 PM
- Pages: 3
- Report this Essay
Hexa Reports
Market Research Reports and Insightful Company Profiles
Geriatric Medicine Treat Age-related Diseases Market
Share, Size, Trends, Growth, Analysis and Outlook
Research Report by Hexa Reports
More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer
from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This
significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of
emergency admissions in elderly people is drug-related.
Browse Detail Report With TOC @ http://www.hexareports.com/report/geriatric-medicinedevelopment-carving-out-new-opportunities-to-treat-age-related-diseases/details
There remains a lack of clinical data to support prescription decisions as relatively few medicines have
been clinically evaluated in age-appropriate patients. In addition, many drugs are not available in
formulations that are suitable for the elderly, leading to non-compliance and lack of therapeutic
efficacy. In 2011, the EMA introduced its Geriatric Medicines Strategy to ensure that the medical
requirements of older people are identified earlier in the drug development process. In 2012, the ICH E7
guidelines were revised to include a greater focus on involving more geriatric patients in drug trials.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/89659
Scope
- Reviews the current regulatory landscape and helps sponsors to understand the potential impact of
recent guidelines.
- Assesses the barriers to entry in geriatric medicines and identifies potential ways to overcome them
and improve clinical decision making.
Hexa Reports
Market Research Reports and Insightful Company Profiles
- Evaluates the importance of establishing Target Quality Product Profiles (TQPP) to help sponsors
determine the target patient population earlier on in drug development.
- Identifies treatment gaps and commercial...
Market Research Reports and Insightful Company Profiles
Geriatric Medicine Treat Age-related Diseases Market
Share, Size, Trends, Growth, Analysis and Outlook
Research Report by Hexa Reports
More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer
from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This
significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of
emergency admissions in elderly people is drug-related.
Browse Detail Report With TOC @ http://www.hexareports.com/report/geriatric-medicinedevelopment-carving-out-new-opportunities-to-treat-age-related-diseases/details
There remains a lack of clinical data to support prescription decisions as relatively few medicines have
been clinically evaluated in age-appropriate patients. In addition, many drugs are not available in
formulations that are suitable for the elderly, leading to non-compliance and lack of therapeutic
efficacy. In 2011, the EMA introduced its Geriatric Medicines Strategy to ensure that the medical
requirements of older people are identified earlier in the drug development process. In 2012, the ICH E7
guidelines were revised to include a greater focus on involving more geriatric patients in drug trials.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/89659
Scope
- Reviews the current regulatory landscape and helps sponsors to understand the potential impact of
recent guidelines.
- Assesses the barriers to entry in geriatric medicines and identifies potential ways to overcome them
and improve clinical decision making.
Hexa Reports
Market Research Reports and Insightful Company Profiles
- Evaluates the importance of establishing Target Quality Product Profiles (TQPP) to help sponsors
determine the target patient population earlier on in drug development.
- Identifies treatment gaps and commercial...